Precision BioSciences reports PBGENE-HBV eliminates cccDNA in biopsies; pgRNA loss in 100% of patients

PRECISION BIOSCIENCES INC

Liver biopsy data show 1-log reduction in cccDNA transcripts after two doses at 0.4 mg/kg; indels inactivate remaining <1%.
pgRNA established as biomarker; 100% of patients (n=6) with detectable pgRNA achieved loss, confirmed by biopsy.
HBsAg declines in 100% of patients (n=15); first patient maintains durable decline for over 12 months.
Safety: No DLTs; manageable LNP-related AEs; mitigation protocol resolved Grade 3 hypotension events with no recurrences.
Next steps: expand enrollment, collect additional biopsies, design Part 2 expansion; update expected by end of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.